The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review

Body composition is related to cardiometabolic disorders and is a major driver of the growing incidence of type 2 diabetes mellitus (T2DM). Altered fat distribution and decreased muscle mass are related to dysglycemia and impose adverse health-related outcomes in people with T2DM. Hence, improving b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahangiri, Soodeh, Malek, Mojtaba, Kalra, Sanjay, Khamseh, Mohammad E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597985/
https://www.ncbi.nlm.nih.gov/pubmed/37837581
http://dx.doi.org/10.1007/s13300-023-01481-7
_version_ 1785125453535641600
author Jahangiri, Soodeh
Malek, Mojtaba
Kalra, Sanjay
Khamseh, Mohammad E.
author_facet Jahangiri, Soodeh
Malek, Mojtaba
Kalra, Sanjay
Khamseh, Mohammad E.
author_sort Jahangiri, Soodeh
collection PubMed
description Body composition is related to cardiometabolic disorders and is a major driver of the growing incidence of type 2 diabetes mellitus (T2DM). Altered fat distribution and decreased muscle mass are related to dysglycemia and impose adverse health-related outcomes in people with T2DM. Hence, improving body composition and maintaining muscle mass is crucial in T2DM. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are novel glucose-lowering medications gaining popularity because of their cardiorenal-protective effects and weight-lowering characteristics. However, reports on myopathy secondary to SGLT2 inhibitor treatment raised a safety concern. The importance of maintaining muscle mass in people with T2DM necessitates further investigation to explore the impact of novel medications on body composition. In this review, we discussed current evidence on the impact of SGLT2 inhibitors on body composition in people with T2DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01481-7.
format Online
Article
Text
id pubmed-10597985
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-105979852023-10-26 The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review Jahangiri, Soodeh Malek, Mojtaba Kalra, Sanjay Khamseh, Mohammad E. Diabetes Ther Review Body composition is related to cardiometabolic disorders and is a major driver of the growing incidence of type 2 diabetes mellitus (T2DM). Altered fat distribution and decreased muscle mass are related to dysglycemia and impose adverse health-related outcomes in people with T2DM. Hence, improving body composition and maintaining muscle mass is crucial in T2DM. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are novel glucose-lowering medications gaining popularity because of their cardiorenal-protective effects and weight-lowering characteristics. However, reports on myopathy secondary to SGLT2 inhibitor treatment raised a safety concern. The importance of maintaining muscle mass in people with T2DM necessitates further investigation to explore the impact of novel medications on body composition. In this review, we discussed current evidence on the impact of SGLT2 inhibitors on body composition in people with T2DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01481-7. Springer Healthcare 2023-10-14 2023-12 /pmc/articles/PMC10597985/ /pubmed/37837581 http://dx.doi.org/10.1007/s13300-023-01481-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Jahangiri, Soodeh
Malek, Mojtaba
Kalra, Sanjay
Khamseh, Mohammad E.
The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
title The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
title_full The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
title_fullStr The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
title_full_unstemmed The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
title_short The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
title_sort effects of sodium–glucose cotransporter 2 inhibitors on body composition in type 2 diabetes mellitus: a narrative review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597985/
https://www.ncbi.nlm.nih.gov/pubmed/37837581
http://dx.doi.org/10.1007/s13300-023-01481-7
work_keys_str_mv AT jahangirisoodeh theeffectsofsodiumglucosecotransporter2inhibitorsonbodycompositionintype2diabetesmellitusanarrativereview
AT malekmojtaba theeffectsofsodiumglucosecotransporter2inhibitorsonbodycompositionintype2diabetesmellitusanarrativereview
AT kalrasanjay theeffectsofsodiumglucosecotransporter2inhibitorsonbodycompositionintype2diabetesmellitusanarrativereview
AT khamsehmohammade theeffectsofsodiumglucosecotransporter2inhibitorsonbodycompositionintype2diabetesmellitusanarrativereview
AT jahangirisoodeh effectsofsodiumglucosecotransporter2inhibitorsonbodycompositionintype2diabetesmellitusanarrativereview
AT malekmojtaba effectsofsodiumglucosecotransporter2inhibitorsonbodycompositionintype2diabetesmellitusanarrativereview
AT kalrasanjay effectsofsodiumglucosecotransporter2inhibitorsonbodycompositionintype2diabetesmellitusanarrativereview
AT khamsehmohammade effectsofsodiumglucosecotransporter2inhibitorsonbodycompositionintype2diabetesmellitusanarrativereview

Ejemplares similares